Clinical Trial Update: Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 dose-escalation study in relapsed or refractory Waldenström's macroglobulinemia, terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Snippet

Sponsor: Idera Pharmaceuticals, Inc. | Conditions: Waldenstrom's Macroglobulinemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-08-29